Features
Screener
Stocks Charts
Sign In Sign Up

Cipla Ltd. Fundamental Analysis Revenue, Profits & Valuation

NSE: CIPLA | BSE: 500087 | PHARMACEUTICALS
Price ₹1,474.40 +₹1.20 (+0.08%)
P/E Ratio 30.7 TTM
52-Week Range
Low ₹1,166 High ₹1,673
Market Cap ₹1.19T Trillion
ROE 11.2% Annual

Market data as of Aug 3, 2026

Let's break down Cipla Ltd. (CIPLA) — from its financial performance to how the market is valuing the stock.

Cipla Revenue Trend

Year-over-year, Cipla Ltd. grew revenue by 2.2% — from ₹27,548 Cr in FY2025 to ₹28,163 Cr in FY2026.

A 7.5% CAGR over 10 years is middle-of-the-road. Cipla Ltd.'s top line moved from ₹13,678 Cr to ₹28,163 Cr in that period.

A ₹28,163 Cr revenue base makes Cipla Ltd. a major name in the Indian pharmaceuticals sector.

Cipla Ltd. has posted revenue growth for 10 consecutive years — that's a sustained trend, not a one-off.

Revenue Trend
YearRevenueYoY %
FY2026₹28,163 Cr+2.2%
FY2025₹27,548 Cr+6.9%
FY2024₹25,774 Cr+13.3%
FY2023₹22,753 Cr+4.5%
FY2022₹21,763 Cr

View Cipla Ltd.'s full 10-year revenue trend with CAGR analysis →

Cipla Profitability

Cipla Ltd.'s profitability took a step back in FY2026, with net income falling 26.7% to ₹3,862 Cr.

A drop in net margin from 19.1% to 13.7% in FY2026 suggests costs grew faster than revenue.

Diluted EPS came in at ₹48.00 for FY2026, down from ₹65.24 a year earlier.

Is Cipla Undervalued

Cipla Ltd. shares are currently trading at ₹1,474.40.

Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.

Share Price vs Book Value

10-year trend comparing market price with book value per share

FY 2017 - FY 2026

Cipla last traded at ₹1,474.40, up 0.1% on the day. The stock is 11.9% below its 52-week high of ₹1,673.00; its 52-week low is ₹1,165.70.

Valuation Models

P/E Ratio
Est. fair value

Fair value & verdict with a free account

Sign up free →
DCF
Est. fair value

Fair value & verdict for members

Upgrade →
EPS Growth
Est. fair value

Fair value & verdict for members

Upgrade →

Cipla Shareholding Pattern

Promoter holding is steady at 29.2% — no buying or selling over the past 4 quarters.

Foreign investors held 20.2% of the company as of June 2026, down year-over-year from 24.6%.

Domestic institutions moved their stake up to 34.6% from 30.2% over the past year.

Shareholding Pattern (Last 4 Quarters)
QuarterPromoterFIIDIIPublic
Jun 202629.2%20.2%34.6%15.9%
Mar 202629.2%22.6%32.0%16.2%
Dec 202529.2%23.9%30.7%16.1%
Sep 202529.2%24.6%30.2%16.0%

Track quarterly shareholding changes for Cipla Ltd. →

Cipla Balance Sheet

Proportional view as of 3 Aug 2026. Hover blocks for details.

Assets

Liabilities & Equity

FY2026 total assets: ₹424.96B (up 13.7% YoY from ₹373.87B).

Top categories: Cash & ST Investments (20.5%), Property, Plant & Equipment (16.9%), Other Assets (16.5%).

Of the ₹424.96B in liabilities and equity, 81.2% is shareholder equity, 1.4% is interest-bearing debt, and 17.3% is operating liabilities. Over the year, debt is up 40.1% and equity is up 10.3%.

Balance sheet composition — FY 2026

Assets (values in Indian Rupees, with M = millions, B = billions)
CategoryValue
Cash & ST Investments 86.98B
Receivables 56.20B
Inventories 65.97B
Property, Plant & Equipment 71.73B
Investments 5.44B
Intangibles & Goodwill 68.51B
Other Assets 70.14B
Liabilities and equity (values in Indian Rupees, with M = millions, B = billions)
CategoryValue
Equity 345.20B
Short-term Debt 2.32B
Long-term Debt 3.82B
Trade Payables 32.30B
Other Liabilities 41.32B

View full balance sheet (multi-year) →

What Stands Out About Cipla

In summary, Cipla Ltd. (CIPLA) presents the following picture for fundamental analysts.

Revenue of ₹28,163 Cr in FY2026, up 2.2% year-over-year.

Long-term revenue has been compounding at 7.5% annually over 10 years.

The company is profitable, with a net margin of 13.7% and net income of ₹3,862 Cr.

Unlock Full Analysis

For the complete 10-year financial history with interactive charts and growth analysis, explore Cipla Ltd.'s detailed profile on Craytheon.

Related Stocks